485 related articles for article (PubMed ID: 15662714)
1. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
2. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
[TBL] [Abstract][Full Text] [Related]
3. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
4. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
5. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
7. [Mutation in the MSH2 gene in Muir-Torre syndrome].
Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
9. Muir-Torre syndrome: a case report and review of the literature.
Pettey AA; Walsh JS
Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
[TBL] [Abstract][Full Text] [Related]
10. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
[TBL] [Abstract][Full Text] [Related]
11. Solitary subungual keratoacanthoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis.
Stoebner PE; Fabre C; Delfour C; Joujoux JM; Roger P; Dandurand M; Meunier L
Dermatology; 2009; 219(2):174-8. PubMed ID: 19602866
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability in Muir-Torre syndrome.
Honchel R; Halling KC; Schaid DJ; Pittelkow M; Thibodeau SN
Cancer Res; 1994 Mar; 54(5):1159-63. PubMed ID: 8118799
[TBL] [Abstract][Full Text] [Related]
13. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
[TBL] [Abstract][Full Text] [Related]
14. Muir-Torre syndrome: Diagnostic and screening guidelines.
Jones B; Oh C; Mangold E; Egan CA
Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre syndrome: clinical features and molecular genetic analysis.
Esche C; Kruse R; Lamberti C; Friedl W; Propping P; Lehmann P; Ruzicka T
Br J Dermatol; 1997 Jun; 136(6):913-7. PubMed ID: 9217825
[TBL] [Abstract][Full Text] [Related]
16. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome.
Peris K; Onorati MT; Keller G; Magrini F; Donati P; Muscardin L; Höfler H; Chimenti S
Br J Dermatol; 1997 Sep; 137(3):356-60. PubMed ID: 9349329
[TBL] [Abstract][Full Text] [Related]
17. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
18. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations.
Ponti G; Ponz de Leon M; Maffei S; Pedroni M; Losi L; Di Gregorio C; Gismondi V; Scarselli A; Benatti P; Roncari B; Seidenari S; Pellacani G; Varotti C; Prete E; Varesco L; Roncucci L
Clin Genet; 2005 Nov; 68(5):442-7. PubMed ID: 16207212
[TBL] [Abstract][Full Text] [Related]
19. Muir-Torre syndrome.
Ponti G; Ponz de Leon M
Lancet Oncol; 2005 Dec; 6(12):980-7. PubMed ID: 16321766
[TBL] [Abstract][Full Text] [Related]
20. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.
Fernandez-Flores A
Am J Dermatopathol; 2012 Jun; 34(4):416-22. PubMed ID: 22123265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
